The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Read More…
Industry, Sector and Symbol
Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
Phone480-245-5960
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.79 million
Profitability
Miscellaneous
Employees138
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Joint (NASDAQ:JYNT) Frequently Asked Questions
What is Joint's stock symbol?
Joint trades on the NASDAQ under the ticker symbol "JYNT."
How were Joint's earnings last quarter?
Joint Corp (NASDAQ:JYNT) announced its quarterly earnings data on Thursday, August, 8th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.02 by $0.01. The business earned $11.17 million during the quarter, compared to analyst estimates of $11.08 million. Joint had a return on equity of 114.93% and a net margin of 5.38%. View Joint's Earnings History.
When is Joint's next earnings date?
What guidance has Joint issued on next quarter's earnings?
Joint issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $46.242-48.444 million, compared to the consensus revenue estimate of $46.1 million.
What price target have analysts set for JYNT?
5 brokers have issued 12-month target prices for Joint's shares. Their predictions range from $21.00 to $30.00. On average, they anticipate Joint's stock price to reach $24.40 in the next year. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Joint.
What is the consensus analysts' recommendation for Joint?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Joint.
What are Wall Street analysts saying about Joint stock?
Here are some recent quotes from research analysts about Joint stock:
- 1. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (10/19/2019)
- 2. Maxim Group analysts commented, "Market close, JYNT reported relatively inline 2Q19 revenue results and reiterated 2019 guidance. The company opened 14 franchise clinics in 2Q19 versus our estimate of 17, for a total of 417 franchises. JYNT also opened one greenfield clinic bringing that total up to 51. We are increasing our 2020 revenue estimate as we expect the company to continue to open franchise and greenfield clinics while expanding its national footprint. Also, we are introducing our 2020 quarterly estimates." (8/9/2019)
Has Joint been receiving favorable news coverage?
News stories about JYNT stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Joint earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Joint.
Are investors shorting Joint?
Joint saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,790,000 shares, an increase of 11.9% from the August 15th total of 1,600,000 shares. Based on an average daily volume of 197,800 shares, the short-interest ratio is presently 9.0 days. Currently, 13.8% of the shares of the stock are sold short. View Joint's Current Options Chain.
Who are some of Joint's key competitors?
Some companies that are related to Joint include TiVo (TIVO), Digital Turbine (APPS), Liberty Tax (TAXA), Quarterhill (QTRH), Acacia Research (ACTG), Research Frontiers (REFR), Finjan (FNJN), XCel Brands (XELB), Marathon Patent Group (MARA), ARC Group (ARCK), MGT Capital Investments (MGTI), XpresSpa Group (XSPA), Spherix (SPEX), Patriot Scientific (PTSC) and American Restaurant Partners LP Class A Partnership Units (ICTPU).
What other stocks do shareholders of Joint own?
Who are Joint's key executives?
Joint's management team includes the folowing people:
- Mr. Peter D. Holt, CEO, Pres & Director (Age 60)
- Jake Singleton, Chief Financial Officer (Age 37)
- Mr. Jorge Armenteros, VP of Operations
- Dr. James Edwards, Chief Chiropractic & Compliance Officer
- Mr. Craig P. Colmar, Sec. (Age 66)
When did Joint IPO?
(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.
Who are Joint's major shareholders?
Joint's stock is owned by many different of retail and institutional investors. Top institutional investors include Calamos Advisors LLC (0.55%), Perkins Capital Management Inc. (0.40%), Strs Ohio (0.17%), Rhumbline Advisers (0.08%) and Winslow Evans & Crocker Inc. (0.01%). Company insiders that own Joint stock include James H Amos Jr, John P Meloun, Peter D Holt and Ronald V Davella. View Institutional Ownership Trends for Joint.
Which major investors are selling Joint stock?
Which major investors are buying Joint stock?
JYNT stock was bought by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Strs Ohio, Winslow Evans & Crocker Inc. and Rhumbline Advisers. Company insiders that have bought Joint stock in the last two years include James H Amos Jr and Peter D Holt. View Insider Buying and Selling for Joint.
How do I buy shares of Joint?
Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Joint's stock price today?
One share of JYNT stock can currently be purchased for approximately $20.09.
How big of a company is Joint?
Joint has a market capitalization of $278.13 million and generates $31.79 million in revenue each year. The company earns $250,000.00 in net income (profit) each year or $0.04 on an earnings per share basis. Joint employs 138 workers across the globe.View Additional Information About Joint.
What is Joint's official website?
How can I contact Joint?
Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]
MarketBeat Community Rating for Joint (NASDAQ JYNT)
MarketBeat's community ratings are surveys of what our community members think about Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
